News
![4 Incredible Dividend Stocks Yielding 4%-Plus to Buy in 2024: https://g.foolcdn.com/editorial/images/759627/cash-money-hundred-dollar-bills.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTc5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2e379a48846e0331970b305ca853add31aba0f82/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/cash-money-hundred-dollar-bills.jpg?locale=us)
4 Incredible Dividend Stocks Yielding 4%-Plus to Buy in 2024
Dividend stocks can be incredible investments. They've historically outperformed the market over the long term. The best returns have come from companies that routinely increase their dividends.
![Is Medtronic's High-Yielding Dividend in Danger?: https://g.foolcdn.com/editorial/images/759498/people-looking-at-a-chart-on-a-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNzM5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1491e7f0b59d9d5161a1e3f561fd97f5f8d2cc52/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/people-looking-at-a-chart-on-a-laptop.jpg?locale=us)
Is Medtronic's High-Yielding Dividend in Danger?
High-yielding dividend stocks can make for great investments because they allow you to earn a lot more in dividends than you would with the average stock.
Today, the average dividend yield for an
![3 Stocks That Could Be Monster Winners in 2024: https://g.foolcdn.com/editorial/images/759574/chart-asian-woman-pointing.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNVg5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b9029c295d8367b56c2c4aac482f1299ec4c13a7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/chart-asian-woman-pointing.jpg?locale=us)
3 Stocks That Could Be Monster Winners in 2024
Finding stocks that are huge winners is easy, in retrospect. Doing so before they take off is an entirely different story. However, it's not an impossible task.
Three Motley Fool contributors think
![2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now: https://g.foolcdn.com/editorial/images/759427/investor-smiling-computer.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUQ5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--55e6496049fb56259fa29d6c94b05fd5ad502770/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-smiling-computer.jpg?locale=us)
2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now
While investors may be hoping for a full-throttled bull market to appear in the new year, some great companies with long-term competitive advantages and robust financials remain at reasonable
![3 Things About Sarepta Therapeutics Every Smart Investor Knows: https://g.foolcdn.com/editorial/images/759359/biotech-pharma-researchers-talk-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN2I4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4e20f07bb520e5b3402232bdf46d1993bc265b18/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/biotech-pharma-researchers-talk-lab.jpg?locale=us)
3 Things About Sarepta Therapeutics Every Smart Investor Knows
Biotech stocks are often challenging for investors to evaluate without having a full scientific context, and Sarepta Therapeutics (NASDAQ: SRPT) is no exception. With multiple successful products on
![Could Pfizer Be a No-Brainer Stock to Buy Right Now, Even If Its COVID Sales Continue to Plunge?: https://g.foolcdn.com/editorial/images/759358/scientist-with-head-down.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGo4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2bc1f2f2e1695fa2eacaca3299f5a4a1b555fff7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientist-with-head-down.jpg?locale=us)
Could Pfizer Be a No-Brainer Stock to Buy Right Now, Even If Its COVID Sales Continue to Plunge?
You might call it a "Pfizzle."
In late 2021, Pfizer (NYSE: PFE) stock was at an all-time high. The company had pulled off a near miracle with its rapid development of a COVID-19 vaccine.
It followed
![3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow: https://g.foolcdn.com/editorial/images/757049/vertex-sign.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN0g3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cea13c0f11fba85605e95cc9baa34dce01ec4a12/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/vertex-sign.png?locale=us)
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Sometimes a company has a mixture of proven performance and upcoming catalysts that make the idea of buying it hand-over-fist practically irresistible. And that's exactly what Vertex Pharmaceuticals
![AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why: https://g.foolcdn.com/editorial/images/758830/person-working-in-pharmacy.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMG43YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b47b13d30cfea6affddc3c03086600081c7d1e1f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-working-in-pharmacy.jpg?locale=us)
AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why
Drug patents don't last forever, so pharmaceutical companies are constantly looking for the next big treatment to broaden their total portfolio of offerings.
When it was clear a few years ago that
![Are Investors Overreacting to Pfizer's Underwhelming Forecast for 2024?: https://g.foolcdn.com/editorial/images/758866/a-frustrated-investor-reviewing-multiple-charts-and-reports.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFg2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--35928bcf22f00ab7a77ce6897c475a80a0235c10/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-frustrated-investor-reviewing-multiple-charts-and-reports.jpg?locale=us)
Are Investors Overreacting to Pfizer's Underwhelming Forecast for 2024?
Pfizer (NYSE: PFE) stock has been in the dumps this year. It is struggling due to declining demand for its COVID products. And it may take some years before its top line starts rising meaningfully
![Editas Just Caught a Break Thanks to Vertex Pharmaceuticals: https://g.foolcdn.com/editorial/images/758926/scientists-lab-testing-blood-draw.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGI2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--10b8ddd90825585a271d2f54ec18566b1715e04b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-lab-testing-blood-draw.jpg?locale=us)
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals
It's fair to say that Editas Medicine (NASDAQ: EDIT) is an ailing biotech. Over the past three years, its share price has fallen by 83% as it abandoned parts of its pipeline and laid off staff
![Could CRISPR Therapeutics Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/758864/rich-couple-on-a-boat.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMEQ2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--767cfe309f38f3762102129d905ab21ccd57c1fb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/rich-couple-on-a-boat.jpg?locale=us)
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
If you're looking for a stock that has the potential to grow your investment to $1 million, a good move may be to invest in a strong business that's in a fast-growing industry. Gene therapy is an
![Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?: https://g.foolcdn.com/editorial/images/758683/vertex.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeGo2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--09b5038c02adacafbd157df278676da99080390f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/vertex.png?locale=us)
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
Could the rare-disease-focused biotech Sarepta Therapeutics (NASDAQ: SRPT) one day become a towering, innovative, and profitable growth business, as biopharma Vertex Pharmaceuticals (NASDAQ: VRTX)
![Will UnitedHealth Group Be a Trillion-Dollar Stock by 2030?: https://g.foolcdn.com/editorial/images/758513/doctor-meeting-a-salesperson.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzM2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a092da54d1b0534ad8f9632c39486b03655ba728/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-meeting-a-salesperson.jpg?locale=us)
Will UnitedHealth Group Be a Trillion-Dollar Stock by 2030?
UnitedHealth Group (NYSE: UNH) has a market capitalization of close to $500 billion and is one of the largest healthcare stocks you can invest in today. That means if it were to double in value, it
![Where Will Regeneron Pharmaceuticals Be in 1 Year?: https://g.foolcdn.com/editorial/images/758512/a-team-of-scientists-reviewing-results-in-a-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzc2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dab3e0fdd1a98f71f46bd606336db9412495b391/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-team-of-scientists-reviewing-results-in-a-lab.jpg?locale=us)
Where Will Regeneron Pharmaceuticals Be in 1 Year?
Regeneron Pharmaceuticals (NASDAQ: REGN) is a growing biotech company that generates a ton of free cash flow. Over the years, it has obtained approval or authorization for 12 medicines. Its strong
![Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?: https://g.foolcdn.com/editorial/images/758888/a-person-delivering-a-presentation-getty.jpg](https://www.sharewise.com/rails/active_storage/blobs/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN0g1YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e9c435a82c770ae966a499d236620b800dcd5ee1/a-person-delivering-a-presentation-getty.jpg?locale=us)
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?
Investors looking for stocks that can make dramatic gains fairly quickly got what they wanted from CRISPR Therapeutics (NASDAQ: CRSP) this year. The stock is up more than 60% in 2023 after the
![Better Growth Stock: AbbVie vs. Abbott Laboratories: https://g.foolcdn.com/editorial/images/758510/doctor-showing-patient-a-chart.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBejM1YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b28e585a4e349a62e4008c1299baec0d23180000/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-showing-patient-a-chart.jpg?locale=us)
Better Growth Stock: AbbVie vs. Abbott Laboratories
Drugmaker AbbVie (NYSE: ABBV) spun off from Abbott Laboratories (NYSE: ABT) at the start of 2013. The growth-oriented pharma business has become a beast, generating more than $58 billion in revenue
![The Top Healthcare Stocks to Buy With $100: https://g.foolcdn.com/editorial/images/758297/physician-talking-to-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBei81YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4dd42755889a4f24ba5c812439cc7708eed1f131/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-talking-to-patient.jpg?locale=us)
The Top Healthcare Stocks to Buy With $100
How much money does one need to start investing in stocks? $1 million? $10,000? The truth is, even a relatively modest sum of $100 is enough to get started for two reasons. First, nowadays, it isn't
![6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy: https://g.foolcdn.com/editorial/images/758499/scientists-studying-dna.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd241YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e401e9f9cd9c77e3cc1dd97a15c8320a51192385/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-studying-dna.jpg?locale=us)
6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy
December has been a big month for CRISPR Therapeutics (NASDAQ: CRSP). On Dec. 8, the Food and Drug Administration (FDA) granted approval for CRISPR's gene-editing therapy, Casgevy, as a treatment
![Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer Stock: https://g.foolcdn.com/editorial/images/758640/dna-on-monitor-scientists.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNVA0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5c2625e119ed9ef4032ecea2146fd4e79b5fe594/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dna-on-monitor-scientists.jpg?locale=us)
Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer Stock
"The thrill of victory and the agony of defeat."
That phrase became well-known years ago thanks to sportscaster Jim McKay. And it pretty much sums up the different trajectories for CRISPR
![Is Vertex Pharmaceuticals Sitting on a Gold Mine?: https://g.foolcdn.com/editorial/images/758783/gettyimages-two-researchers-work-in-a-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNm40YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a0da424ffd22e96677a6fa841ca69b0244b7778c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-two-researchers-work-in-a-lab.jpg?locale=us)
Is Vertex Pharmaceuticals Sitting on a Gold Mine?
Vertex Pharmaceuticals (NASDAQ: VRTX) has brought in billions of dollars in earnings over time thanks to its leadership in the market for cystic fibrosis (CF) treatment. And along with partner
![This Big Pharma Is Teaming Up With Nvidia to Make Drugs With AI. Here's What You Need to Know: https://g.foolcdn.com/editorial/images/758429/nvidia-headquarters-with-grey-nvidia-sign-in-front-with-nvidia-logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1Q0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--286303723e7ccf20cb8fcae5f241cdc4a03f2629/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/nvidia-headquarters-with-grey-nvidia-sign-in-front-with-nvidia-logo.png?locale=us)
This Big Pharma Is Teaming Up With Nvidia to Make Drugs With AI. Here's What You Need to Know
In late November, Roche's (OTC: RHHBY) subsidiary Genentech and the chipmaker Nvidia (NASDAQ: NVDA) agreed to collaborate on developing new medicines using artificial intelligence (AI) over the next
![Better Dividend Stock: Pfizer or British American Tobacco?: https://g.foolcdn.com/editorial/images/758771/piggybank.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOXIzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--697fff1ca15d9c827ac6b2fea1830ca80f8f2694/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/piggybank.jpg?locale=us)
Better Dividend Stock: Pfizer or British American Tobacco?
Dividend stocks offer attractive features for income and growth investors alike. On the income side, many blue chip dividend stocks sport higher yields than those of risk-free assets such as the
![Want $1,500 in Dividend Income in 2024? Invest $25,000 in These 3 Top Income Stocks: https://g.foolcdn.com/editorial/images/758508/a-person-smiling-and-reviewing-their-finances.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNUQzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1cbb917e785009b568e11f2a45559e68b0090653/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-person-smiling-and-reviewing-their-finances.jpg?locale=us)
Want $1,500 in Dividend Income in 2024? Invest $25,000 in These 3 Top Income Stocks
Dividend income can boost your overall returns, and also provide you with some recurring cash flow for your portfolio. That's a good thing, because it means you don't have to sell your investments
![3 Stocks Near Multiyear Lows That Could Bounce Back in 2024: https://g.foolcdn.com/editorial/images/758501/analyst-looking-at-charts.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM0QzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9b375a6728ded57505b845081eabb4f50d2904dd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/analyst-looking-at-charts.jpg?locale=us)
3 Stocks Near Multiyear Lows That Could Bounce Back in 2024
When a company underperforms, the markets sometimes have a tendency to overreact. An earnings miss or a guidance cut can at times be enough to lead to a significant sell-off, even if the underlying
![3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow: https://g.foolcdn.com/editorial/images/758605/investors-look-at-tablet-outside.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNEwzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a530481e1f80216f50f5db9d1a7bd13d16ff701e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investors-look-at-tablet-outside.jpg?locale=us)
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow
CRISPR Therapeutics (NASDAQ: CRSP) has climbed more than 60% this year -- and for good reason. The company and partner Vertex Pharmaceuticals delivered positive results from clinical trials of their